This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAlerisLife（FSQA）株式概要AlerisLife Inc. operates and manages senior living communities in the United States. 詳細FSQA ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長2/6過去の実績0/6財務の健全性4/6配当金0/6報酬収益は年間68.88%増加すると予測されています 同業他社や業界と比較して、良好な取引価格 リスク分析キャッシュランウェイが1年未満である German市場と比較して、過去 3 か月間の株価の変動が非常に大きい意味のある時価総額がありません ( €41M )過去1年間で株主の希薄化が進んだ +1 さらなるリスクすべてのリスクチェックを見るFSQA Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW474,562 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA474,562 investors already sharing narrativesYour Fair Value€Current Price€1.21該当なし内在価値ディスカウントEst. Revenue$PastFuture-60m2b2016201920222025202620282031Revenue US$2.2bEarnings US$157.8mAdvancedSet Fair ValueView all narrativesAlerisLife Inc. 競合他社Maternus-KlinikenSymbol: XTRA:MAKMarket cap: €19.9mGesundheitswelt ChiemgauSymbol: MUN:JTH0Market cap: €22.4mMEDICLINSymbol: XTRA:MEDMarket cap: €196.7mLIMES SchlossklinikenSymbol: XTRA:LIKMarket cap: €171.3m価格と性能株価の高値、安値、推移の概要AlerisLife過去の株価現在の株価US$1.2152週高値US$2.1852週安値US$0.51ベータ0.961ヶ月の変化0.83%3ヶ月変化77.94%1年変化-40.10%3年間の変化-47.84%5年間の変化-88.25%IPOからの変化-96.64%最新ニュースRecent Insider Transactions • Mar 21Chairman & MD recently bought €27m worth of stockOn the 18th of March, Adam Portnoy bought around 22m shares on-market at roughly €1.23 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months.Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. MD, Secretary & Director Jennifer Clark was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 05ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million.ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million on February 2, 2023. Under the terms of the transaction, ABP Acquisition will commence a tender offer to acquire all of the outstanding shares of AlerisLife at a price of $1.31 per share in cash. Post the transaction ABP Acquisition, ABP Trust and Adam D. Portnoy who currently own 6.1% stake of AlerisLife will own 100%. The transaction is subject to among other things, a number of shares being tendered in the tender offer that, together with the shares owned by ABP and its affiliates, represent a majority of ALR shares. Diversified Healthcare Trust which holds approximately 31.9% of the outstanding shares of ALR common stock, has also consented to the transaction and has agreed to tender its shares in the tender offer. Based on the recommendation of the special committee of Board, the Board of Directors of AlerisLife have unanimously approved the transaction. The transaction is expected to be completed in the first quarter of 2023. Faiz Ahmad of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to ABP Acquisition. Zachary Blume and Suni Sreepada of Ropes & Gray LLP acted as legal advisor to AlerisLife. Citigroup Global Markets Inc. acted as financial advisor to AlerisLife and provided fairness opinion to the Special Committee of AlerisLife.お知らせ • Nov 11AlerisLife Inc. Receives a Notification Letter from Nasdaq Regarding Minimum Bid PriceOn November 7, 2022, AlerisLife Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, for the last 30 consecutive business days, the bid price of its shares of common stock, par value $0.01 per share (“common shares”), had closed below $1.00 per common share, which is the minimum required closing bid price for continued listing on Nasdaq pursuant to Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until May 8, 2023, to regain compliance with the minimum bid price continued listing standard. To regain compliance, the closing bid price of the common shares must meet or exceed $1.00 per common share for a minimum of 10 consecutive business days during the 180 calendar day grace period. If the Company is not in compliance by May 8, 2023, it may be afforded a second 180 calendar day grace period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq with the exception of the minimum bid price requirement. If the Company does not regain compliance within the allotted period(s), including any extensions that it may receive, Nasdaq will provide notice that the common shares will be subject to delisting. The Company is monitoring the bid price of the common shares and is considering its options to achieve compliance with the minimum bid price continued listing standard.Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.Reported Earnings • Nov 04Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.32 loss in 3Q 2021)Third quarter 2022 results: US$0.27 loss per share (improved from US$0.32 loss in 3Q 2021). Revenue: US$182.7m (up 326% from 3Q 2021). Net loss: US$8.51m (loss narrowed 17% from 3Q 2021). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.最新情報をもっと見るRecent updatesRecent Insider Transactions • Mar 21Chairman & MD recently bought €27m worth of stockOn the 18th of March, Adam Portnoy bought around 22m shares on-market at roughly €1.23 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months.Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. MD, Secretary & Director Jennifer Clark was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 05ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million.ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million on February 2, 2023. Under the terms of the transaction, ABP Acquisition will commence a tender offer to acquire all of the outstanding shares of AlerisLife at a price of $1.31 per share in cash. Post the transaction ABP Acquisition, ABP Trust and Adam D. Portnoy who currently own 6.1% stake of AlerisLife will own 100%. The transaction is subject to among other things, a number of shares being tendered in the tender offer that, together with the shares owned by ABP and its affiliates, represent a majority of ALR shares. Diversified Healthcare Trust which holds approximately 31.9% of the outstanding shares of ALR common stock, has also consented to the transaction and has agreed to tender its shares in the tender offer. Based on the recommendation of the special committee of Board, the Board of Directors of AlerisLife have unanimously approved the transaction. The transaction is expected to be completed in the first quarter of 2023. Faiz Ahmad of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to ABP Acquisition. Zachary Blume and Suni Sreepada of Ropes & Gray LLP acted as legal advisor to AlerisLife. Citigroup Global Markets Inc. acted as financial advisor to AlerisLife and provided fairness opinion to the Special Committee of AlerisLife.お知らせ • Nov 11AlerisLife Inc. Receives a Notification Letter from Nasdaq Regarding Minimum Bid PriceOn November 7, 2022, AlerisLife Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, for the last 30 consecutive business days, the bid price of its shares of common stock, par value $0.01 per share (“common shares”), had closed below $1.00 per common share, which is the minimum required closing bid price for continued listing on Nasdaq pursuant to Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until May 8, 2023, to regain compliance with the minimum bid price continued listing standard. To regain compliance, the closing bid price of the common shares must meet or exceed $1.00 per common share for a minimum of 10 consecutive business days during the 180 calendar day grace period. If the Company is not in compliance by May 8, 2023, it may be afforded a second 180 calendar day grace period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq with the exception of the minimum bid price requirement. If the Company does not regain compliance within the allotted period(s), including any extensions that it may receive, Nasdaq will provide notice that the common shares will be subject to delisting. The Company is monitoring the bid price of the common shares and is considering its options to achieve compliance with the minimum bid price continued listing standard.Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.Reported Earnings • Nov 04Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.32 loss in 3Q 2021)Third quarter 2022 results: US$0.27 loss per share (improved from US$0.32 loss in 3Q 2021). Revenue: US$182.7m (up 326% from 3Q 2021). Net loss: US$8.51m (loss narrowed 17% from 3Q 2021). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.お知らせ • Oct 18Alerislife Inc. Appoints Philip Benjamson as Senior Vice President and Chief Operating OfficerThe Board of Directors of AlerisLife Inc. (the “Company”) has appointed Philip Benjamson as Senior Vice President and Chief Operating Officer of the Company, effective October 17, 2022. Prior to joining the Company, Mr. Benjamson, 55, served as Vice President-Senior Housing Operations at Trinity Health Senior Communities since May 2021. Prior to Trinity Health Senior Communities, Mr. Benjamson served as Chief Operating Officer at Resort Lifestyle Communities from July 2018 to May 2021 and at Blake Management Group from December 2016 to July 2018. Prior to those roles, Mr. Benjamson held several leadership roles in sales and marketing at senior living companies. Mr. Benjamson holds a Bachelor of Arts in Organizational Development from the University of California, Davis. Mr. Benjamson has advised the Company that he has no arrangements or understandings with any other person pursuant to which he was appointed Senior Vice President and Chief Operating Officer. He also advised the Company that he has no family relationships with any director, executive officer or any person nominated or chosen by the Company to become a director or executive officer of the Company.お知らせ • Oct 06AlerisLife Inc. to Report Q3, 2022 Results on Nov 02, 2022AlerisLife Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 02, 2022お知らせ • Sep 20+ 1 more updateAlerisLife Inc. Announces Chief Financial Officer ChangesThe Board of Directors of AlerisLife Inc. has appointed Heather Pereira as Chief Financial Officer of the Company, effective September 19, 2022. Ms. Pereira succeeds Jeffrey C. Leer, who will continue to serve as the Company’s President and Chief Executive Officer. Prior to joining the Company, Ms. Pereira, 47, held financial and accounting roles of increasing responsibility at Acushnet Holdings Corp. since 2004, including Vice President and Corporate Controller from May 2017 through August 2022 and Controller between May 2014 and May 2017. Prior to Acushnet, Ms. Pereira served as Accounting Manager at Cognos Incorporated from 2002 to 2004 and was an Associate at Arthur Andersen LLP from 2002 through 2004. Ms. Pereira is a certified public accountant and holds a Master of Science in Accountancy and a Master of Business Administration from Northeastern University.Breakeven Date Change • Aug 09No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$1.66m in 2024.Reported Earnings • Aug 05Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.39 loss in 2Q 2021)Second quarter 2022 results: US$0.28 loss per share (up from US$0.39 loss in 2Q 2021). Revenue: US$39.7m (down 15% from 2Q 2021). Net loss: US$8.81m (loss narrowed 28% from 2Q 2021). Over the next year, revenue is forecast to grow 389%, compared to a 2.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.お知らせ • Jul 07AlerisLife Inc. to Report Q2, 2022 Results on Aug 03, 2022AlerisLife Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 03, 2022Reported Earnings • May 05First quarter 2022 earnings released: US$0.31 loss per share (vs US$0.10 profit in 1Q 2021)First quarter 2022 results: US$0.31 loss per share (down from US$0.10 profit in 1Q 2021). Revenue: US$173.2m (up 243% from 1Q 2021). Net loss: US$9.73m (down 394% from profit in 1Q 2021). Over the next year, revenue is forecast to grow 902%, compared to a 5.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.お知らせ • May 03+ 1 more updateAlerisLife Inc. Announces Management ChangesAlerisLife Inc. announced that it has named Jeff Leer as Interim President, effective May 1, 2022. Mr. Leer has served as Executive Vice President, Chief Financial Officer and Treasurer of ALR since 2019 and will continue these responsibilities. Mr. Leer succeeds Katie Potter, who resigned as President and Chief Executive Officer, effective April 30, 2022. Prior to joining AlerisLife in 2019, Mr. Leer held senior accounting and finance positions at The RMR Group and its affiliates, including serving as Chief Financial Officer and Treasurer of Office Properties Income Trust.Breakeven Date Change • Apr 27Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.Breakeven Date Change • Apr 07Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.お知らせ • Apr 07AlerisLife Inc., Annual General Meeting, Jun 07, 2022AlerisLife Inc., Annual General Meeting, Jun 07, 2022, at 09:30 US Eastern Standard Time. Agenda: To consider the election of the Director nominees to Board of Directors; to consider the approval of the second amended and restated 2014 Equity Compensation Plan; to ratify the appointment of Deloitte & Touche LLP as independent auditors to serve for the 2022 fiscal year; and to transact such other business as may properly come before the meeting and at any postponements or adjournments of the meeting.お知らせ • Apr 06AlerisLife Inc. to Report Q1, 2022 Results on May 03, 2022AlerisLife Inc. announced that they will report Q1, 2022 results After-Market on May 03, 2022Recent Insider Transactions • Mar 05Insider recently bought €91k worth of stockOn the 1st of March, Lauren Cody bought around 40k shares on-market at roughly €2.27 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Feb 25Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$0.95 loss per share (down from US$0.24 loss in FY 2020). Revenue: US$180.1m (down 19% from FY 2020). Net loss: US$29.9m (loss widened 294% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 329%, compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.お知らせ • Feb 02AlerisLife Inc. to Report Q4, 2021 Results on Feb 23, 2022AlerisLife Inc. announced that they will report Q4, 2021 results After-Market on Feb 23, 2022Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.12 profit in 3Q 2020)The company reported a decent third quarter result with improved revenues, although earnings and control over costs were weaker. Third quarter 2021 results: Revenue: US$225.8m (up 311% from 3Q 2020). Net loss: US$10.2m (down 375% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 2 analysts covering Five Star Senior Living expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$2.15m in 2022. Average annual earnings growth of 120% is required to achieve expected profit on schedule.Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.39 loss per share (vs US$0.095 profit in 2Q 2020)The company reported a decent second quarter result with improved revenues, although earnings and control over costs were weaker. Second quarter 2021 results: Revenue: US$258.6m (up 374% from 2Q 2020). Net loss: US$12.3m (down US$15.3m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Breakeven Date Change • Aug 06Forecast breakeven pushed back to 2022The 2 analysts covering Five Star Senior Living previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 26% to 2021. The company is expected to make a profit of US$7.69m in 2022. Average annual earnings growth of 146% is required to achieve expected profit on schedule.お知らせ • Jun 28+ 4 more updatesFive Star Senior Living Inc.(NasdaqCM:FVE) dropped from Russell 3000E Value IndexFive Star Senior Living Inc.(NasdaqCM:FVE) dropped from Russell 3000E Value IndexValuation Update With 7 Day Price Move • May 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$5.10, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 28x in the Healthcare industry in Germany. Total loss to shareholders of 49% over the past three years.Reported Earnings • May 07First quarter 2021 earnings released: EPS US$0.10 (vs US$0.55 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$276.9m (up 366% from 1Q 2020). Net income: US$3.32m (up US$20.5m from 1Q 2020). Profit margin: 1.2% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Mar 04New 90-day low: €5.20The company is down 1.0% from its price of €5.25 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 9.0% over the same period.Executive Departure • Mar 02Chief Accounting Officer has left the companyOn the 23rd of February, Ellen Snow's tenure as Chief Accounting Officer ended after 1.5 years in the role. As of December 2020, Ellen personally held only 2.50k shares (€14k worth at the time). Ellen is the only executive to leave the company over the last 12 months.Reported Earnings • Feb 27Full year 2020 earnings released: US$0.24 loss per share (vs US$3.99 loss in FY 2019)The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: US$221.9m (down 80% from FY 2019). Net loss: US$7.59m (loss narrowed 62% from FY 2019). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to US$6.75, the stock is trading at a trailing P/E ratio of 38.3x, up from the previous P/E ratio of 32.9x. This compares to an average P/E of 19x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 44%.Is New 90 Day High Low • Feb 06New 90-day high: €6.75The company is up 70% from its price of €3.98 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 7.0% over the same period.お知らせ • Feb 02Five Star Senior Living Inc. Partners with CVS to Administer Vaccines to Shop Community Residents and Staff, Which Commenced in December 2020Five Star Senior Living Inc. has partnered with CVS to administer vaccines to SHOP community residents and staff, which commenced in December 2020. DHC expects vaccination clinics for SHOP community residents and staff to be substantially complete by the end of the first quarter of 2021. As it pertains to DHC’s SHOP segment, as of January 29, 2021. Approximately 18,000 total residents and staff, or more than 65% of residents and more than 30% of staff at DHC’s SHOP communities, have received vaccinations. This includes over 2,000 residents and staff who have received both doses of the vaccine; Approximately 93% of DHC’s SHOP communities are currently open to new admissions; and; Approximately 3.5% of DHC’s total SHOP community residents have or have had active cases of COVID-19, and approximately 67% of those who have tested positive for COVID-19 during the pandemic have since recovered, as defined by CDC guidelines. For the months ended September 30, October 31, November 30 and December 31, 2020, average occupancies in DHC’s SHOP segment were 74.5%, 73.8%, 72.5%, and 70.7%, respectively. Although occupancy has declined because of reduced move-ins by residents, sales leads have increased substantially since the end of 2020. The rolling four-week average sales leads as of January 24, 2021 were 83% higher than the rolling four-week average sales leads at the beginning of the fourth quarter of 2020.お知らせ • Jan 29Five Star Senior Living Inc. to Report Q4, 2020 Results on Feb 24, 2021Five Star Senior Living Inc. announced that they will report Q4, 2020 results After-Market on Feb 24, 2021Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improved over the past weekAfter last week's 16% share price gain to US$6.65, the stock is trading at a trailing P/E ratio of 35.7x, up from the previous P/E ratio of 30.9x. This compares to an average P/E of 17x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 46%.Is New 90 Day High Low • Dec 12New 90-day high: €6.05The company is up 33% from its price of €4.54 on 11 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 4.0% over the same period.Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 19% share price gain to US$5.85, the stock is trading at a trailing P/E ratio of 31.4x, up from the previous P/E ratio of 26.3x. This compares to an average P/E of 18x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 55%.Valuation Update With 7 Day Price Move • Dec 05Market bids up stock over the past weekAfter last week's 15% share price gain to US$5.65, the stock is trading at a trailing P/E ratio of 31.7x, up from the previous P/E ratio of 27.5x. This compares to an average P/E of 18x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 55%.Is New 90 Day High Low • Nov 24New 90-day high: €4.60The company is up 5.0% from its price of €4.38 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period.Valuation Update With 7 Day Price Move • Nov 12Market bids up stock over the past weekAfter last week's 18% share price gain to US$4.42, the stock is trading at a trailing P/E ratio of 23x, up from the previous P/E ratio of 19.5x. This compares to an average P/E of 19x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 70%.Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS US$0.12The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$295.3m (up 7.7% from 3Q 2019). Net income: US$3.72m (up US$10.8m from 3Q 2019). Profit margin: 1.3% (up from net loss in 3Q 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Oct 29New 90-day low: €3.74The company is down 1.0% from its price of €3.78 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 15% over the same period.お知らせ • Oct 10Five Star Senior Living Inc. to Report Q3, 2020 Results on Nov 05, 2020Five Star Senior Living Inc. announced that they will report Q3, 2020 results at 9:00 AM, Eastern Standard Time on Nov 05, 2020お知らせ • Jul 10Five Star Senior Living Inc. to Report Q2, 2020 Results on Aug 06, 2020Five Star Senior Living Inc. announced that they will report Q2, 2020 results at 9:00 AM, Eastern Standard Time on Aug 06, 2020株主還元FSQADE HealthcareDE 市場7D0.8%2.0%1.2%1Y-40.1%2.9%0.7%株主還元を見る業界別リターン: FSQA過去 1 年間で2.9 % の収益を上げたGerman Healthcare業界を下回りました。リターン対市場: FSQAは、過去 1 年間で0.7 % のリターンを上げたGerman市場を下回りました。価格変動Is FSQA's price volatile compared to industry and market?FSQA volatilityFSQA Average Weekly Movement20.9%Healthcare Industry Average Movement5.7%Market Average Movement5.4%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.7%安定した株価: FSQAの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: FSQAの 週次ボラティリティ は、過去 1 年間で14%から21%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト20018,600Jeff Leerwww.alerislife.comもっと見るAlerisLife Inc. 基礎のまとめAlerisLife の収益と売上を時価総額と比較するとどうか。FSQA 基礎統計学時価総額€41.18m収益（TTM）-€35.24m売上高(TTM)€148.96m0.3xP/Sレシオ-1.2xPER（株価収益率FSQA は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計FSQA 損益計算書（TTM）収益US$159.70m売上原価US$90.05m売上総利益US$69.65mその他の費用US$107.43m収益-US$37.78m直近の収益報告Sep 30, 2022次回決算日該当なし一株当たり利益（EPS）-1.13グロス・マージン43.61%純利益率-23.66%有利子負債／自己資本比率43.8%FSQA の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/03/21 23:01終値2023/03/17 00:00収益2022/09/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AlerisLife Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関Bryan MaherB. Riley Securities, Inc.Joseph FranceCantor Fitzgerald & Co.Peter MartinCitizens JMP Securities, LLC7 その他のアナリストを表示
Recent Insider Transactions • Mar 21Chairman & MD recently bought €27m worth of stockOn the 18th of March, Adam Portnoy bought around 22m shares on-market at roughly €1.23 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months.
Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. MD, Secretary & Director Jennifer Clark was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 05ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million.ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million on February 2, 2023. Under the terms of the transaction, ABP Acquisition will commence a tender offer to acquire all of the outstanding shares of AlerisLife at a price of $1.31 per share in cash. Post the transaction ABP Acquisition, ABP Trust and Adam D. Portnoy who currently own 6.1% stake of AlerisLife will own 100%. The transaction is subject to among other things, a number of shares being tendered in the tender offer that, together with the shares owned by ABP and its affiliates, represent a majority of ALR shares. Diversified Healthcare Trust which holds approximately 31.9% of the outstanding shares of ALR common stock, has also consented to the transaction and has agreed to tender its shares in the tender offer. Based on the recommendation of the special committee of Board, the Board of Directors of AlerisLife have unanimously approved the transaction. The transaction is expected to be completed in the first quarter of 2023. Faiz Ahmad of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to ABP Acquisition. Zachary Blume and Suni Sreepada of Ropes & Gray LLP acted as legal advisor to AlerisLife. Citigroup Global Markets Inc. acted as financial advisor to AlerisLife and provided fairness opinion to the Special Committee of AlerisLife.
お知らせ • Nov 11AlerisLife Inc. Receives a Notification Letter from Nasdaq Regarding Minimum Bid PriceOn November 7, 2022, AlerisLife Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, for the last 30 consecutive business days, the bid price of its shares of common stock, par value $0.01 per share (“common shares”), had closed below $1.00 per common share, which is the minimum required closing bid price for continued listing on Nasdaq pursuant to Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until May 8, 2023, to regain compliance with the minimum bid price continued listing standard. To regain compliance, the closing bid price of the common shares must meet or exceed $1.00 per common share for a minimum of 10 consecutive business days during the 180 calendar day grace period. If the Company is not in compliance by May 8, 2023, it may be afforded a second 180 calendar day grace period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq with the exception of the minimum bid price requirement. If the Company does not regain compliance within the allotted period(s), including any extensions that it may receive, Nasdaq will provide notice that the common shares will be subject to delisting. The Company is monitoring the bid price of the common shares and is considering its options to achieve compliance with the minimum bid price continued listing standard.
Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.
Reported Earnings • Nov 04Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.32 loss in 3Q 2021)Third quarter 2022 results: US$0.27 loss per share (improved from US$0.32 loss in 3Q 2021). Revenue: US$182.7m (up 326% from 3Q 2021). Net loss: US$8.51m (loss narrowed 17% from 3Q 2021). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Mar 21Chairman & MD recently bought €27m worth of stockOn the 18th of March, Adam Portnoy bought around 22m shares on-market at roughly €1.23 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was Adam's only on-market trade for the last 12 months.
Board Change • Mar 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 4 highly experienced directors. MD, Secretary & Director Jennifer Clark was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 05ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million.ABP Acquisition LLC entered into an agreement to acquire the remaining 93.7% stake in AlerisLife Inc. (NasdaqCM:ALR) from Diversified Healthcare Trust (NasdaqGS:DHC) and others for $41.2 million on February 2, 2023. Under the terms of the transaction, ABP Acquisition will commence a tender offer to acquire all of the outstanding shares of AlerisLife at a price of $1.31 per share in cash. Post the transaction ABP Acquisition, ABP Trust and Adam D. Portnoy who currently own 6.1% stake of AlerisLife will own 100%. The transaction is subject to among other things, a number of shares being tendered in the tender offer that, together with the shares owned by ABP and its affiliates, represent a majority of ALR shares. Diversified Healthcare Trust which holds approximately 31.9% of the outstanding shares of ALR common stock, has also consented to the transaction and has agreed to tender its shares in the tender offer. Based on the recommendation of the special committee of Board, the Board of Directors of AlerisLife have unanimously approved the transaction. The transaction is expected to be completed in the first quarter of 2023. Faiz Ahmad of Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisor to ABP Acquisition. Zachary Blume and Suni Sreepada of Ropes & Gray LLP acted as legal advisor to AlerisLife. Citigroup Global Markets Inc. acted as financial advisor to AlerisLife and provided fairness opinion to the Special Committee of AlerisLife.
お知らせ • Nov 11AlerisLife Inc. Receives a Notification Letter from Nasdaq Regarding Minimum Bid PriceOn November 7, 2022, AlerisLife Inc. (the “Company”) received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that, for the last 30 consecutive business days, the bid price of its shares of common stock, par value $0.01 per share (“common shares”), had closed below $1.00 per common share, which is the minimum required closing bid price for continued listing on Nasdaq pursuant to Listing Rule 5550(a)(2). Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until May 8, 2023, to regain compliance with the minimum bid price continued listing standard. To regain compliance, the closing bid price of the common shares must meet or exceed $1.00 per common share for a minimum of 10 consecutive business days during the 180 calendar day grace period. If the Company is not in compliance by May 8, 2023, it may be afforded a second 180 calendar day grace period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq with the exception of the minimum bid price requirement. If the Company does not regain compliance within the allotted period(s), including any extensions that it may receive, Nasdaq will provide notice that the common shares will be subject to delisting. The Company is monitoring the bid price of the common shares and is considering its options to achieve compliance with the minimum bid price continued listing standard.
Breakeven Date Change • Nov 08No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$6.45m in 2024.
Reported Earnings • Nov 04Third quarter 2022 earnings released: US$0.27 loss per share (vs US$0.32 loss in 3Q 2021)Third quarter 2022 results: US$0.27 loss per share (improved from US$0.32 loss in 3Q 2021). Revenue: US$182.7m (up 326% from 3Q 2021). Net loss: US$8.51m (loss narrowed 17% from 3Q 2021). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 89% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
お知らせ • Oct 18Alerislife Inc. Appoints Philip Benjamson as Senior Vice President and Chief Operating OfficerThe Board of Directors of AlerisLife Inc. (the “Company”) has appointed Philip Benjamson as Senior Vice President and Chief Operating Officer of the Company, effective October 17, 2022. Prior to joining the Company, Mr. Benjamson, 55, served as Vice President-Senior Housing Operations at Trinity Health Senior Communities since May 2021. Prior to Trinity Health Senior Communities, Mr. Benjamson served as Chief Operating Officer at Resort Lifestyle Communities from July 2018 to May 2021 and at Blake Management Group from December 2016 to July 2018. Prior to those roles, Mr. Benjamson held several leadership roles in sales and marketing at senior living companies. Mr. Benjamson holds a Bachelor of Arts in Organizational Development from the University of California, Davis. Mr. Benjamson has advised the Company that he has no arrangements or understandings with any other person pursuant to which he was appointed Senior Vice President and Chief Operating Officer. He also advised the Company that he has no family relationships with any director, executive officer or any person nominated or chosen by the Company to become a director or executive officer of the Company.
お知らせ • Oct 06AlerisLife Inc. to Report Q3, 2022 Results on Nov 02, 2022AlerisLife Inc. announced that they will report Q3, 2022 results at 4:00 PM, US Eastern Standard Time on Nov 02, 2022
お知らせ • Sep 20+ 1 more updateAlerisLife Inc. Announces Chief Financial Officer ChangesThe Board of Directors of AlerisLife Inc. has appointed Heather Pereira as Chief Financial Officer of the Company, effective September 19, 2022. Ms. Pereira succeeds Jeffrey C. Leer, who will continue to serve as the Company’s President and Chief Executive Officer. Prior to joining the Company, Ms. Pereira, 47, held financial and accounting roles of increasing responsibility at Acushnet Holdings Corp. since 2004, including Vice President and Corporate Controller from May 2017 through August 2022 and Controller between May 2014 and May 2017. Prior to Acushnet, Ms. Pereira served as Accounting Manager at Cognos Incorporated from 2002 to 2004 and was an Associate at Arthur Andersen LLP from 2002 through 2004. Ms. Pereira is a certified public accountant and holds a Master of Science in Accountancy and a Master of Business Administration from Northeastern University.
Breakeven Date Change • Aug 09No longer forecast to breakevenThe 2 analysts covering AlerisLife no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$1.16m in 2024. New consensus forecast suggests the company will make a loss of US$1.66m in 2024.
Reported Earnings • Aug 05Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.39 loss in 2Q 2021)Second quarter 2022 results: US$0.28 loss per share (up from US$0.39 loss in 2Q 2021). Revenue: US$39.7m (down 15% from 2Q 2021). Net loss: US$8.81m (loss narrowed 28% from 2Q 2021). Over the next year, revenue is forecast to grow 389%, compared to a 2.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
お知らせ • Jul 07AlerisLife Inc. to Report Q2, 2022 Results on Aug 03, 2022AlerisLife Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 03, 2022
Reported Earnings • May 05First quarter 2022 earnings released: US$0.31 loss per share (vs US$0.10 profit in 1Q 2021)First quarter 2022 results: US$0.31 loss per share (down from US$0.10 profit in 1Q 2021). Revenue: US$173.2m (up 243% from 1Q 2021). Net loss: US$9.73m (down 394% from profit in 1Q 2021). Over the next year, revenue is forecast to grow 902%, compared to a 5.7% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 124% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
お知らせ • May 03+ 1 more updateAlerisLife Inc. Announces Management ChangesAlerisLife Inc. announced that it has named Jeff Leer as Interim President, effective May 1, 2022. Mr. Leer has served as Executive Vice President, Chief Financial Officer and Treasurer of ALR since 2019 and will continue these responsibilities. Mr. Leer succeeds Katie Potter, who resigned as President and Chief Executive Officer, effective April 30, 2022. Prior to joining AlerisLife in 2019, Mr. Leer held senior accounting and finance positions at The RMR Group and its affiliates, including serving as Chief Financial Officer and Treasurer of Office Properties Income Trust.
Breakeven Date Change • Apr 27Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.
Breakeven Date Change • Apr 07Forecast breakeven date pushed back to 2024The 2 analysts covering AlerisLife previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 57% per year to 2023. The company is expected to make a profit of US$7.23m in 2024. Average annual earnings growth of 80% is required to achieve expected profit on schedule.
お知らせ • Apr 07AlerisLife Inc., Annual General Meeting, Jun 07, 2022AlerisLife Inc., Annual General Meeting, Jun 07, 2022, at 09:30 US Eastern Standard Time. Agenda: To consider the election of the Director nominees to Board of Directors; to consider the approval of the second amended and restated 2014 Equity Compensation Plan; to ratify the appointment of Deloitte & Touche LLP as independent auditors to serve for the 2022 fiscal year; and to transact such other business as may properly come before the meeting and at any postponements or adjournments of the meeting.
お知らせ • Apr 06AlerisLife Inc. to Report Q1, 2022 Results on May 03, 2022AlerisLife Inc. announced that they will report Q1, 2022 results After-Market on May 03, 2022
Recent Insider Transactions • Mar 05Insider recently bought €91k worth of stockOn the 1st of March, Lauren Cody bought around 40k shares on-market at roughly €2.27 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Feb 25Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$0.95 loss per share (down from US$0.24 loss in FY 2020). Revenue: US$180.1m (down 19% from FY 2020). Net loss: US$29.9m (loss widened 294% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 329%, compared to a 4.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 119% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
お知らせ • Feb 02AlerisLife Inc. to Report Q4, 2021 Results on Feb 23, 2022AlerisLife Inc. announced that they will report Q4, 2021 results After-Market on Feb 23, 2022
Reported Earnings • Nov 05Third quarter 2021 earnings released: US$0.32 loss per share (vs US$0.12 profit in 3Q 2020)The company reported a decent third quarter result with improved revenues, although earnings and control over costs were weaker. Third quarter 2021 results: Revenue: US$225.8m (up 311% from 3Q 2020). Net loss: US$10.2m (down 375% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Sep 23Forecast to breakeven in 2022The 2 analysts covering Five Star Senior Living expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$2.15m in 2022. Average annual earnings growth of 120% is required to achieve expected profit on schedule.
Reported Earnings • Aug 06Second quarter 2021 earnings released: US$0.39 loss per share (vs US$0.095 profit in 2Q 2020)The company reported a decent second quarter result with improved revenues, although earnings and control over costs were weaker. Second quarter 2021 results: Revenue: US$258.6m (up 374% from 2Q 2020). Net loss: US$12.3m (down US$15.3m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 87% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Aug 06Forecast breakeven pushed back to 2022The 2 analysts covering Five Star Senior Living previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 26% to 2021. The company is expected to make a profit of US$7.69m in 2022. Average annual earnings growth of 146% is required to achieve expected profit on schedule.
お知らせ • Jun 28+ 4 more updatesFive Star Senior Living Inc.(NasdaqCM:FVE) dropped from Russell 3000E Value IndexFive Star Senior Living Inc.(NasdaqCM:FVE) dropped from Russell 3000E Value Index
Valuation Update With 7 Day Price Move • May 12Investor sentiment improved over the past weekAfter last week's 18% share price gain to US$5.10, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 28x in the Healthcare industry in Germany. Total loss to shareholders of 49% over the past three years.
Reported Earnings • May 07First quarter 2021 earnings released: EPS US$0.10 (vs US$0.55 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$276.9m (up 366% from 1Q 2020). Net income: US$3.32m (up US$20.5m from 1Q 2020). Profit margin: 1.2% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Mar 04New 90-day low: €5.20The company is down 1.0% from its price of €5.25 on 03 December 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Healthcare industry, which is down 9.0% over the same period.
Executive Departure • Mar 02Chief Accounting Officer has left the companyOn the 23rd of February, Ellen Snow's tenure as Chief Accounting Officer ended after 1.5 years in the role. As of December 2020, Ellen personally held only 2.50k shares (€14k worth at the time). Ellen is the only executive to leave the company over the last 12 months.
Reported Earnings • Feb 27Full year 2020 earnings released: US$0.24 loss per share (vs US$3.99 loss in FY 2019)The company reported a soft full year result with weaker revenues and control over costs, although losses reduced. Full year 2020 results: Revenue: US$221.9m (down 80% from FY 2019). Net loss: US$7.59m (loss narrowed 62% from FY 2019). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment improved over the past weekAfter last week's 16% share price gain to US$6.75, the stock is trading at a trailing P/E ratio of 38.3x, up from the previous P/E ratio of 32.9x. This compares to an average P/E of 19x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 44%.
Is New 90 Day High Low • Feb 06New 90-day high: €6.75The company is up 70% from its price of €3.98 on 06 November 2020. The German market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 7.0% over the same period.
お知らせ • Feb 02Five Star Senior Living Inc. Partners with CVS to Administer Vaccines to Shop Community Residents and Staff, Which Commenced in December 2020Five Star Senior Living Inc. has partnered with CVS to administer vaccines to SHOP community residents and staff, which commenced in December 2020. DHC expects vaccination clinics for SHOP community residents and staff to be substantially complete by the end of the first quarter of 2021. As it pertains to DHC’s SHOP segment, as of January 29, 2021. Approximately 18,000 total residents and staff, or more than 65% of residents and more than 30% of staff at DHC’s SHOP communities, have received vaccinations. This includes over 2,000 residents and staff who have received both doses of the vaccine; Approximately 93% of DHC’s SHOP communities are currently open to new admissions; and; Approximately 3.5% of DHC’s total SHOP community residents have or have had active cases of COVID-19, and approximately 67% of those who have tested positive for COVID-19 during the pandemic have since recovered, as defined by CDC guidelines. For the months ended September 30, October 31, November 30 and December 31, 2020, average occupancies in DHC’s SHOP segment were 74.5%, 73.8%, 72.5%, and 70.7%, respectively. Although occupancy has declined because of reduced move-ins by residents, sales leads have increased substantially since the end of 2020. The rolling four-week average sales leads as of January 24, 2021 were 83% higher than the rolling four-week average sales leads at the beginning of the fourth quarter of 2020.
お知らせ • Jan 29Five Star Senior Living Inc. to Report Q4, 2020 Results on Feb 24, 2021Five Star Senior Living Inc. announced that they will report Q4, 2020 results After-Market on Feb 24, 2021
Valuation Update With 7 Day Price Move • Dec 17Investor sentiment improved over the past weekAfter last week's 16% share price gain to US$6.65, the stock is trading at a trailing P/E ratio of 35.7x, up from the previous P/E ratio of 30.9x. This compares to an average P/E of 17x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 46%.
Is New 90 Day High Low • Dec 12New 90-day high: €6.05The company is up 33% from its price of €4.54 on 11 September 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 4.0% over the same period.
Valuation Update With 7 Day Price Move • Dec 08Market bids up stock over the past weekAfter last week's 19% share price gain to US$5.85, the stock is trading at a trailing P/E ratio of 31.4x, up from the previous P/E ratio of 26.3x. This compares to an average P/E of 18x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 55%.
Valuation Update With 7 Day Price Move • Dec 05Market bids up stock over the past weekAfter last week's 15% share price gain to US$5.65, the stock is trading at a trailing P/E ratio of 31.7x, up from the previous P/E ratio of 27.5x. This compares to an average P/E of 18x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 55%.
Is New 90 Day High Low • Nov 24New 90-day high: €4.60The company is up 5.0% from its price of €4.38 on 26 August 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period.
Valuation Update With 7 Day Price Move • Nov 12Market bids up stock over the past weekAfter last week's 18% share price gain to US$4.42, the stock is trading at a trailing P/E ratio of 23x, up from the previous P/E ratio of 19.5x. This compares to an average P/E of 19x in the Healthcare industry in Germany. Total return to shareholders over the past three years is a loss of 70%.
Reported Earnings • Nov 07Third quarter 2020 earnings released: EPS US$0.12The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: US$295.3m (up 7.7% from 3Q 2019). Net income: US$3.72m (up US$10.8m from 3Q 2019). Profit margin: 1.3% (up from net loss in 3Q 2019). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Oct 29New 90-day low: €3.74The company is down 1.0% from its price of €3.78 on 30 July 2020. The German market is down 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 15% over the same period.
お知らせ • Oct 10Five Star Senior Living Inc. to Report Q3, 2020 Results on Nov 05, 2020Five Star Senior Living Inc. announced that they will report Q3, 2020 results at 9:00 AM, Eastern Standard Time on Nov 05, 2020
お知らせ • Jul 10Five Star Senior Living Inc. to Report Q2, 2020 Results on Aug 06, 2020Five Star Senior Living Inc. announced that they will report Q2, 2020 results at 9:00 AM, Eastern Standard Time on Aug 06, 2020
